Marinus Pharmaceuticals, Inc.
GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
Last updated:
Abstract:
The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
Status:
Application
Type:
Utility
Filling date:
1 Mar 2022
Issue date:
7 Jul 2022